UK Clears Oral Psoriasis Pill Already Used in US

IcotydeWhat to know

30-second read

For Dermatology · Rheumatology

Who

Adults and adolescents 12+ (≥40 kg) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Not approved for psoriatic arthritis.

What’s new

MHRA’s 23 October approval makes the UK the third major market — after the US (March) and EU (September) — for icotrokinra, the first oral IL-23 receptor blocker.

Evidence

Head-to-head ICONIC-ADVANCE trials: complete clearance (IGA 0) in ∼37% on icotrokinra vs. ∼16-17% on deucravacitinib at week 16 (p<0.001).

Big advantage

Biologic-grade IL-23 blockade as a once-daily pill — no self-injection, filled through the pharmacy benefit rather than an infusion suite.

Key consideration

Carries the IL-23-class infection and TB-screening warnings; most US plans require prior authorization and step therapy through a preferred biologic first.

Availability

US-available since March 2026 (∼$8,285 WAC per 30-tablet pack, ∼$100K/year undiscounted); UK NHS funding is a separate, still-open NICE appraisal.

Practice impactConsider for selected patients

A legitimate oral alternative for patients who want to avoid self-injection, now with head-to-head evidence against the other oral option. Not shown superior to injectable biologics directly, and most payers still gate it behind step therapy.

Read the full physician analysis

Full analysis · 9 min readMHRA approval (23 Oct 2026) · FDA approval letter, NDA 220149 · ICONIC-LEAD & ICONIC-ADVANCE trials

The UK’s medicines regulator approved icotrokinra, sold as Icotyde, on 23 October 2026 — the third major-market clearance in eight months for the first oral peptide built to selectively block the IL-23 receptor, a target that until now has only been druggable by injection. For most US dermatologists the UK news changes nothing about Monday’s clinic: Johnson & Johnson’s drug has been FDA-approved and dispensed since March. What has changed since then is the evidence available to position it — specifically, head-to-head trial results against deucravacitinib, the only other oral systemic option, that give prescribers an actual number to work from instead of two separate placebo comparisons.

The Head-to-Head Data Against Deucravacitinib

Icotrokinra’s initial approvals rested on the ICONIC-LEAD trial: 684 adults and adolescents, where 50% reached PASI 90 at week 16 against 4% on placebo (p<0.001), rising to roughly 65% PASI 90 and 74% IGA 0/1 by week 24. That established efficacy against placebo — useful for a regulator, less useful for a dermatologist already comfortable with injectable IL-23 biologics or already prescribing Bristol Myers Squibb’s deucravacitinib (Sotyktu), the TYK2 inhibitor that has held the only other oral slot in systemic psoriasis therapy since 2022. The ICONIC-ADVANCE 1 and 2 trials close that gap: randomized, active-comparator studies that put icotrokinra directly against deucravacitinib, not just against placebo.

ICONIC-ADVANCE 1 & 2 at week 16

37% vs. 16-17%complete clearance (IGA score of 0), icotrokinra vs. deucravacitinib, both studies

31-32% vs. 11-14%PASI 100 (total clearance), icotrokinra vs. deucravacitinib

p<0.001for every icotrokinra-vs-deucravacitinib comparison reported above

684participants in ICONIC-LEAD, the separate placebo-controlled trial behind the original approval

From Johnson & Johnson's and Protagonist Therapeutics' topline results disclosures for the ICONIC-ADVANCE program. Full peer-reviewed results may refine these figures; treat the ranges as the two separate ADVANCE studies, not a single pooled result.

The company reports the advantage held through week 24 and that adverse-event rates on icotrokinra ran numerically lower than on deucravacitinib over the same window — a comparison worth watching for the full peer-reviewed publication rather than taking on a press release alone. Johnson & Johnson has also started ICONIC-ASCEND, a head-to-head trial against ustekinumab (Stelara), which would eventually give dermatologists a comparison against an injectable biologic as well; that trial has not reported.

What Changes When IL-23 Blockade Comes in a Pill

Every other approved IL-23-pathway therapy for psoriasis — AbbVie’s risankizumab (Skyrizi) among them — is an injectable biologic. Icotrokinra is described by the company and corroborated by independent trade coverage as a targeted oral peptide engineered to achieve comparable receptor selectivity to a biologic while being taken as a 200 mg tablet once a day. The practical effect is mostly logistical, not pharmacological: no injection-technique training visit, no cold-chain storage at home, and dispensing that typically runs through a patient’s pharmacy benefit rather than the medical benefit or an infusion suite. For a patient whose psoriasis is well-controlled on an injectable but who finds the injection itself the obstacle — needle aversion, travel, a job that makes refrigerated storage impractical — that is a genuine access improvement. It is not evidence that oral IL-23 blockade outperforms injectable IL-23 blockade; no trial has tested icotrokinra against risankizumab or guselkumab (Tremfya) directly.

Three systemic options for moderate-to-severe plaque psoriasis

	Icotyde (icotrokinra)	Sotyktu (deucravacitinib)	Skyrizi (risankizumab)
Route / frequency	Oral tablet, once daily	Oral tablet, once daily	Subcutaneous injection, every 12 weeks after induction
Mechanism	Targeted oral peptide, selective IL-23 receptor blocker	TYK2 inhibitor, acts further downstream in the IL-23/IL-12 pathway	Monoclonal antibody, binds the IL-23 p19 subunit directly
Adolescent indication	Yes, 12 years and older (≥40 kg)	No, adults only	No, adults only
Psoriatic arthritis	Not approved	Not approved for PsA	Approved for active psoriatic arthritis
Comparative evidence	Superior to deucravacitinib head-to-head (ICONIC-ADVANCE); no trial vs. injectable IL-23 biologics yet	Established since 2022; now outperformed head-to-head by icotrokinra on complete clearance	No head-to-head trial against icotrokinra; years of real-world injectable-biologic experience

Each drug's figures come from its own label and trial program. The icotrokinra-vs-deucravacitinib row is the one genuine head-to-head comparison here; the other cells are cross-trial context, not direct comparisons, and should be read with that caveat.

The Guardrails: Infections, TB and What's Still Unapproved

Icotyde carries the warnings standard to the IL-23 class: an increased risk of infections, a recommendation to evaluate patients for tuberculosis before starting and to avoid use in patients with an active, clinically important infection, and caution around administering live vaccines during treatment. The most common adverse reactions in trials, each occurring in at least 1% of patients, were headache, nausea, cough, fungal infection and fatigue; through week 16, adverse events ran close to placebo rates, and no new safety signal had emerged through 52 weeks of pooled follow-up across more than 600 patients. For rheumatologists, the more consequential limit is the indication itself: Icotyde is approved for skin disease only. A patient who is clear on Icotyde but develops new joint pain has not had their psoriatic arthritis treated by the same prescription — that still requires a therapy with its own PsA evidence and approval, something risankizumab, guselkumab and several injectable IL-23 and IL-17 agents already have and icotrokinra does not.

Where Payers Still Say No First

US list price for Icotyde runs about $8,285 (WAC) for a 30-tablet, 200 mg supply — roughly $100,000 a year undiscounted, in the same range as the injectable biologics it is meant to offer an alternative to. Johnson & Johnson’s savings program can bring a commercially insured patient’s cost as low as $0 a month, subject to a program cap, but that does not substitute for a plan's own coverage decision. Nearly every major US payer's pharmacy policy on file requires prior authorization, and several — Aetna's Medicaid formularies among them — require documented step therapy through a preferred biologic, or apremilast (Otezla), before Icotyde is approved. In the UK, the practical gap is a different one entirely: MHRA's approval is a marketing authorization, not a funding decision, and NHS access depends on a National Institute for Health and Care Excellence technology appraisal that was still under way as of this approval. A UK prescriber who reads news of the MHRA decision and assumes the drug is now available on the NHS would be acting ahead of the actual funding timeline.

• Positioning against deucravacitinib. ICONIC-ADVANCE gives a real comparative reason to prefer icotrokinra on efficacy, particularly for patients seeking complete, not just adequate, clearance — weigh that against deucravacitinib's longer track record.
• Adolescents. Icotrokinra is the only oral systemic option approved down to age 12, a real differentiator from both deucravacitinib and apremilast for pediatric dermatology referrals.
• Not a psoriatic-arthritis drug. Flag this explicitly for patients and co-managing rheumatologists — joint symptoms need their own evaluation and therapy regardless of how the skin responds.
• Expect a prior-authorization fight on a treatment-naive patient. Most US plans want documented failure or intolerance of a preferred biologic or apremilast first; build that record before prescribing if first-line use is the goal.
• Screen before starting. TB evaluation and a check for active infection belong in the same visit as the decision to prescribe, not an afterthought.

None of this makes icotrokinra the obvious first prescription for every psoriasis patient; it makes it a better-characterized one than it was in March. The UK joining the US and EU closes out the drug's rollout across the three regulatory regions prescribers watch most closely. The more useful fact for a Friday clinic list is the one buried in the trial data: for a patient already weighing an oral option, there is now a real number distinguishing the two available choices, not just two separate comparisons against placebo.

Frequently asked questions

Is icotrokinra (Icotyde) approved for psoriatic arthritis?

No. Icotyde's approval, in the US, EU and now the UK, covers moderate-to-severe plaque psoriasis only. It has not been studied or approved for psoriatic arthritis, and rheumatologists should not treat a patient's joint disease on the strength of this label — a patient already doing well on Icotyde for skin disease who develops joint symptoms still needs a separate PsA-appropriate therapy.

How does Icotyde compare with deucravacitinib (Sotyktu), the other oral option?

In the head-to-head ICONIC-ADVANCE 1 and 2 trials, icotrokinra showed superior skin clearance to deucravacitinib at week 16: complete clearance (IGA score of 0) in roughly 37% of patients on icotrokinra versus 16-17% on deucravacitinib, and PASI 100 in roughly 31-32% versus 11-14% (all comparisons p<0.001, per Johnson & Johnson's topline results). Adverse-event rates were numerically lower on icotrokinra through week 24. Deucravacitinib remains the only oral option with longer real-world experience and no adolescent indication; icotrokinra is approved down to age 12.

Will a patient's insurance cover Icotyde, and what will it cost?

US list price (WAC) runs about $8,285 for a 30-tablet, 200 mg pack, roughly $100,000 a year undiscounted; commercially insured patients may pay as little as $0 a month through the manufacturer's savings program, subject to a cap. Most major US payers require prior authorization, and several, including Aetna's Medicaid plans, require a documented trial of a preferred biologic or apremilast first. In the UK, MHRA's approval is a safety-and-efficacy decision only; NHS funding runs through a separate NICE technology appraisal still under way.